ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.

Authors: Siamak Daneshmand, Stephen A. Boorjian, Joshua J. Meeks, Trinity Bivalacqua, Yair Lotan, Wassim Kassouf, Girish S. Kulkarni, Paolo Gontero, Peter Albers, Joern Skibsted Jakobsen, Kristian Juul

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4630

Source: Full article

---

Abstract

TPS4630